Haven-1 Experience Debuted by Vast
New Partners Announced for Orbital Research
The unveiling of the first-ever immersive experience of Haven-1, the world’s first commercial space station, was conducted by Vast at the recent Space Symposium in Colorado Springs. The company also made two significant announcements at the show.
"With Haven-1, we aim to redefine what’s possible in biotechnology and pharmaceuticals."
Max Hoat, Vast
The Haven-1 Experience gave attendees a hands-on opportunity to witness the state-of-the-art design and advanced functionality that will be aboard the space station. The immersive experience featured the hatch, crew interface displays, crew storage, and crew quarters, which include the revolutionary zero-gravity sleep system. It also showcased the Haven-1 Lab, with installed payloads from current payload partners, and the 1.1 m (3.6 foot) domed window that offers an expansive, 180-degree view of Earth from the space station.
The company announced that Japan Manned Space Systems Corporation (JAMSS), Interstellar Lab, and Exobiosphere are the latest payload partners for its Haven-1 Lab. The three companies—leaders in space systems, biotechnology, and pharmaceutical research—join existing Haven-1 Lab partners Redwire and Yuri, reinforcing Vast’s mission to enable international collaboration in low-Earth orbit (LEO) and accelerate scientific breakthroughs that benefit humanity and support long-term space habitation. The new partners will leverage the microgravity environment of the Haven-1 Lab by installing payloads focused in the areas of advanced materials development, biotechnology, and pharmaceutical development.
“We are honored to welcome our new partners to the Haven-1 Lab—an essential step toward building a thriving ecosystem for science, innovation, and collaboration in space. These partnerships reflect a growing global recognition that microgravity is not just a research environment, but a catalyst for transformative breakthroughs. With Haven-1, we aim to redefine what’s possible in biotechnology and pharmaceuticals—accelerating discovery, enhancing safety, and unlocking new frontiers for life on Earth and beyond,” said Max Haot, CEO of Vast.
Vast also further solidified its commitment to advancing space-based research by announcing a new agreement with the Center for the Advancement of Science in Space (CASIS). This agreement with CASIS, manager of the ISS National Lab, allows us to act as a key collaborator to support research aboard the ISS and strengthen our private astronaut mission (PAM) readiness.